Login to Your Account



Post-consolidation, biotechs should consider selling their assets back to pharma

By Nuala Moran
Staff Writer

Wednesday, May 13, 2015
LONDON – Restructuring and reshaping of the pharma industry across the globe has resulted in significant fallout in terms of programs, redundant facilities and skills. At the same time there has been significant externalization of R&D.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription